Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
about
Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjectsMaraviroc: a review of its use in HIV infection and beyondMaraviroc modelling strategy: use of early phase 1 data to support a semi-mechanistic population pharmacokinetic model.Development and bioanalytical validation of a liquid chromatographic-tandem mass spectrometric (LC-MS/MS) method for the quantification of the CCR5 antagonist maraviroc in human plasma.Assessment of the pharmacokinetics of co-administered maraviroc and raltegravirDrug interactions with new and investigational antiretrovirals.Maternal-fetal pharmacokinetics and dynamics of a single intrapartum dose of maraviroc in rhesus macaquesCYP3A5 genotype impacts maraviroc concentrations in healthy volunteers.Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men.Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.Hypersensitivity reactions to HIV therapy.Switching antiretroviral therapy to minimize metabolic complications.HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.Impaired maraviroc and raltegravir clearance in a human immunodeficiency virus-infected patient with end-stage liver disease and renal impairment: a management dilemma.Use of antineoplastic agents in patients with cancer who have HIV/AIDS.Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial.Cytochrome P450 3A5 plays a prominent role in the oxidative metabolism of the anti-human immunodeficiency virus drug maravirocEffects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteersEffect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.Pharmacokinetic interaction between maraviroc and fosamprenavir-ritonavir: an open-label, fixed-sequence study in healthy subjects.The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.Treatment of HIV infection with the CCR5 antagonist maraviroc.Clinical utility of maraviroc.Drug safety evaluation of maraviroc for the treatment of HIV infection.Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic in vitro-in vivo extrapolation of oral drug absorption.Targeting CCR5 for anti-HIV research.Maraviroc - A CCR5 Antagonist for the Treatment of HIV-1 Infection.Maraviroc plus raltegravir failed to maintain virological suppression in HIV-infected patients with lipohypertrophy: results from the ROCnRAL ANRS 157 study.Development of maraviroc, a CCR5 antagonist for treatment of HIV, using a novel tropism assay.Pharmacokinetic profile and safety of 150 mg of maraviroc dosed with 800/100 mg of darunavir/ritonavir all once daily, with and without nucleoside analogues, in HIV-infected subjects.Pharmacokinetic interaction of maraviroc with tacrolimus in a patient coinfected with HIV and hepatitis B virus following hepatic transplant due to hepatocellular carcinoma.From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.Use of in vitro to in vivo extrapolation to predict the optimal strategy for patients switching from efavirenz to maraviroc or nevirapine.Tipranavir in highly antiretroviral treatment-experienced patients: Results from a French prospective cohortPlasma concentrations of maraviroc and raltegravir after dual therapy in patients with long-term suppressed viraemia: ROCnRAL ANRS 157 study: Figure 1
P2860
Q24650421-862BEFC5-F647-4B9C-B055-607067A428D8Q26778504-39983C47-4602-4662-B27C-34BFB12486DEQ33501346-5BD14F35-E7E0-4935-B401-666BE2280EE7Q33643626-1F507D13-9F79-4B34-A1ED-A92D35AB2196Q33696575-2EA0B9E2-38A3-4FEF-B9E6-6917CB616CE4Q33801821-E6EE9EF7-A12A-41A6-B719-89E78C957ACFQ34151052-AC0C5BCE-8249-4E20-B8EE-51FB8E93BA19Q34360012-B167DB72-C6D8-40CA-853C-93DF7CE76C3AQ34589333-711F4919-8187-46B5-B2F3-E2B93BB4899EQ34834065-C8FC1424-F0FB-4F3D-AC57-305EF438C15BQ34932654-79AE772F-942C-41DB-8783-0B06AA31EF8DQ34976463-F3BE1F60-3D25-4A01-A906-C1E82B69A42AQ35608074-721EE64A-16CB-4627-8CE0-602870F8A125Q35794988-0800581D-EEB1-449B-A7A5-84C1704317FBQ35898833-C9E66F48-FFF2-4F70-9255-E641E5204991Q35932561-8937B338-C997-4750-B0E1-C12B2ABF1B32Q36084912-61878364-D282-4F27-A8F0-846B51B94369Q36406298-71D6FD61-502C-495E-A4D5-B2F90A9D321DQ36558221-D1DAEC17-3AEC-480E-9EB1-1D728F0C97C7Q36558235-EE053815-0697-4816-9FDA-E9593D03ABA0Q36558247-DD43883F-97A6-4451-8EF5-65F5CD116D39Q37042100-0F34A01D-C2EA-4A17-920B-B9EAADEBE3BAQ37335653-C46EF298-AB1B-4458-8D9D-967ACBB9D2C7Q37591226-D76964FE-982A-4F10-B5B8-B4B50CF86717Q37733565-1CE832A7-9F41-4761-8E9D-01ECAABBAC69Q37877242-9321739F-7143-4F61-A88D-8EB4C0C36E17Q37961188-A99381BA-C926-4516-81DE-0A7B7CD10660Q38038547-C810155A-F318-4985-BA60-1002A52C4F42Q38229805-0190D52B-05B3-4CBD-93D9-7496D411D22FQ38534016-C947EAB8-6767-4071-B92B-0988990EDDE0Q39123448-8F4EC0AA-3C90-4694-98E2-8C8029B70D6FQ39549270-CE6EB441-647A-4BC2-ABCB-2C525DE2F82DQ44938963-DF839761-D767-4EF5-B807-2C4BA844A901Q45353436-0B2A628B-9920-4394-AA37-F26ED744692FQ46697094-A59D0833-CBEF-435D-A9E9-2A74EC36203BQ51051365-35D881A8-D278-4EA0-B409-2FFBF27FC414Q56449116-F3F1C761-9C72-4C3E-BF34-4C9610E77FB8Q59151022-51B0FA0D-CBEF-4C83-BDFB-A4FF7732160A
P2860
Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@ast
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@en
type
label
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@ast
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@en
prefLabel
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@ast
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@en
P2093
P2860
P1476
Assessment of the pharmacokine ...... gonist, in healthy volunteers.
@en
P2093
Caroline E Ridgway
Christine G Medhurst
Elna van der Ryst
Gary J Muirhead
Maria C Rosario
Richard J Taylor-Worth
Samantha Abel
P2860
P356
10.1111/J.1365-2125.2008.03130.X
P407
P478
65 Suppl 1
P577
2008-04-01T00:00:00Z